
Background: CRE/carbapenemase producing Enterobacteriaceae (CPE) is a serious threat to public health. The first epidemic of CRE/CPE in the US was caused by K. pneumoniae producing KPC-2 and 3. A second epidemic, E. cloacae harboring KPC-3, first occurred in North Dakota and Minnesota. We examined rates and temporal trends of carbapenem non-susceptibility (NS) in K. pneumoniae and E. cloacae at VHA facilities.
Methods: Using VHA databases, we identified E. cloacae and K. pneumoniae tested for carbapenem susceptibility isolated in patients hospitalized from 2012 to 2014. Facilities that tested < 90% of isolates were excluded; one isolate per patient was counted. We examined carbapenem NS by year, sorting facilities according to regions designated by the US Department of Health and Human Services.
Results: Among 10,973 E. cloacae and 28,218 K. pneumoniae isolates from VHA facilities in 42 states, the District of Columbia (DC), and Puerto Rico (PR), carbapenem NS was 3.3% and 2.8% for E. cloacae and K. pneumoniae, respectively. Rates among E. cloacae trended upwards to reach above 3% and rates in K. pneumoniae decreased from 3.3% to 2.1% over the 3 years examined. Trends remained after removing PR, which had the highest rates at 12.2% and 23.3%, respectively. The rate of carbapenem NS in E. cloacae exceeded that of K. pneumoniae in all regions except Region 2 (Table and Maps). Despite these regional trends, there were exceptions in several large cities outside of Region 2 with higher rates of NS in K. pneumoniae than in E. cloacae.
Conclusion: Nationwide VHA data suggests a second epidemic of CRE/CPE mediated by E. cloacae. Robust surveillance integrating susceptibility data, resistance mechanisms, genotyping and antibiotic use is essential to understand the changing epidemiology of CRE/CPE in the VHA system.
Region | States | E. cloacae | K. pneumoniae | ||
|
| Range of % NS * | % NS | Range of % NS * | % NS |
1 | ME, VT, RI, MA | 0-3.1 | 2.5 | 0-0.9 | 0.10 |
2 | NY, NJ, PR | 1.0 -12.3 | 6.1 | 0.8-23.5 | 12.1 |
3 | VA, PA, MD, WV, DC | 0-5.8 | 2.4 | 0-4.8 | 2.1 |
4 | AL, GA, MS, NC, SC, TN, FL | 0-5.9 | 2.6 | 0-3.4 | 1.0 |
5 | IL, IN, MI, MN, OH, WI | 0-6.9 | 1.9 | 0-4.3 | 1.8 |
6 | AR, LA, OK, TX | 0-8 | 3.4 | 0-4.7 | 1.9 |
7 | IA, KS, MO, NE | 0-4 | 1.6 | 0-3.8 | 0.8 |
8 | CO, SD, ND, MT, UT, WY | 0-4 | 1.9 | 0-0 | 0.2 |
9 | AZ, CA, NV | 0-11.3 | 4.0 | 0-3.4 | 1.5 |
10 | OR, WA | 0-15.1 | 8.9 | 0-0.6 | 0.3 |
Including facilities with > 30 isolates

F. Perez,
Pfizer:
Grant Investigator
,
Grant recipient
Actavis:
Consultant
,
Consulting fee
S. Patel, None
E. Saade, None
C. J. Donskey, None
R. A. Bonomo, None